Published in PLoS Med on April 01, 2007
AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance. Nat Rev Neurol (2010) 3.28
Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. J Neuroinflammation (2012) 3.12
Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain (2008) 2.96
Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol (2013) 1.79
Cerebrospinal fluid antibodies to aquaporin-4 in neuromyelitis optica and related disorders: frequency, origin, and diagnostic relevance. J Neuroinflammation (2010) 1.60
Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations. J Neurol (2008) 1.46
Neuromyelitis optica: clinical features, immunopathogenesis and treatment. Clin Exp Immunol (2014) 1.38
Sensitive and robust luminescent profiling of anti-La and other autoantibodies in Sjogren's syndrome. Autoimmunity (2009) 1.31
MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation (2016) 1.20
Optical Coherence Tomography Reveals Distinct Patterns of Retinal Damage in Neuromyelitis Optica and Multiple Sclerosis. PLoS One (2013) 1.18
Protective effect of an elastase inhibitor in a neuromyelitis optica-like disease driven by a peptide of myelin oligodendroglial glycoprotein. Mult Scler (2012) 1.10
New insights into neuromyelitis optica. J Clin Neurol (2011) 1.09
MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin. J Neuroinflammation (2016) 1.01
B cells and autoantibodies in the pathogenesis of multiple sclerosis and related inflammatory demyelinating diseases. Adv Immunol (2008) 0.98
Aquaporin-4 autoantibodies in neuromyelitis optica spectrum disorders: comparison between tissue-based and cell-based indirect immunofluorescence assays. J Neuroinflammation (2010) 0.98
Update on biomarkers in neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm (2015) 0.96
Treatment of neuromyelitis optica: current debate. Ther Adv Neurol Disord (2008) 0.95
The problems and promises of research into human immunology and autoimmune disease. Nat Med (2012) 0.94
Differential diagnoses to MS: experiences from an optic neuritis clinic. J Neurol (2013) 0.93
The Immunology of Neuromyelitis Optica-Current Knowledge, Clinical Implications, Controversies and Future Perspectives. Int J Mol Sci (2016) 0.93
Type I interferons as ambiguous modulators of chronic inflammation in the central nervous system. Front Immunol (2012) 0.92
Rapid induction of autoantibodies during ARDS and septic shock. J Transl Med (2010) 0.89
Epigallocatechin-3-gallate: a useful, effective and safe clinical approach for targeted prevention and individualised treatment of neurological diseases? EPMA J (2013) 0.89
Neuromyelitis optica IgG serostatus in fulminant central nervous system inflammatory demyelinating disease. Arch Neurol (2009) 0.86
Ultrahigh field MRI in clinical neuroimmunology: a potential contribution to improved diagnostics and personalised disease management. EPMA J (2015) 0.86
Evaluation of a multiparametric immunofluorescence assay for standardization of neuromyelitis optica serology. PLoS One (2012) 0.85
Central Nervous System Idiopathic Inflammatory Demyelinating Disorders in South Americans: A Descriptive, Multicenter, Cross-Sectional Study. PLoS One (2015) 0.84
Evaluation of aquaporin-4 antibody assays. Clin Exp Neuroimmunol (2014) 0.84
Aquaporin-4 antibody testing: direct comparison of M1-AQP4-DNA-transfected cells with leaky scanning versus M23-AQP4-DNA-transfected cells as antigenic substrate. J Neuroinflammation (2014) 0.83
Imaging the visual pathway in neuromyelitis optica. Mult Scler Int (2011) 0.83
A novel data mining system points out hidden relationships between immunological markers in multiple sclerosis. Immun Ageing (2013) 0.82
Anti-AQP(4) antibody in idiopathic acute transverse myelitis with recurrent clinical course: frequency of positivity and influence in prognosis. J Spinal Cord Med (2012) 0.81
Differentiation of neuromyelitis optica from multiple sclerosis on spinal magnetic resonance imaging. Int J MS Care (2012) 0.78
Homology between Klebsiella pneumoniae and human aquaporin-4: no evidence for cross-reactivity in neuromyelitis optica. A study on 114 patients. J Neurol (2010) 0.78
Clinical usefulness of cell-based indirect immunofluorescence assay for the detection of aquaporin-4 antibodies in neuromyelitis optica spectrum disorder. Ann Lab Med (2012) 0.78
Principles of separation: indications and therapeutic targets for plasma exchange. Clin J Am Soc Nephrol (2013) 0.77
In vivo imaging reveals rapid astrocyte depletion and axon damage in a model of neuromyelitis optica-related pathology. Ann Neurol (2016) 0.77
An immunoassay that distinguishes real neuromyelitis optica signals from a labeling detected in patients receiving natalizumab. BMC Neurol (2014) 0.77
Neuromyelitis optica does not impact periventricular venous density versus healthy controls: a 7.0 Tesla MRI clinical study. MAGMA (2016) 0.77
Systemic Lupus Erythematosus (SLE) Complicated by Neuromyelitis Optica (NMO - Devic's Disease): Clinic-Pathological Report and Review of the Literature. Clin Med Insights Case Rep (2014) 0.75
The role of anti-aquaporin 4 antibody in the conversion of acute brainstem syndrome to neuromyelitis optica. BMC Neurol (2016) 0.75
Finding NMO: The Evolving Diagnostic Criteria of Neuromyelitis Optica. J Neuroophthalmol (2016) 0.75
Screening for onconeural antibodies in neuromyelitis optica spectrum disorders. BMC Neurol (2017) 0.75
Neuromyelitis and more: the unfolding spectrum of aquaporin 4-related neurological diseases. J Neurol (2009) 0.75
Multifrequency magnetic resonance elastography of the brain reveals tissue degeneration in neuromyelitis optica spectrum disorder. Eur Radiol (2016) 0.75
Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol (2001) 24.36
Revised diagnostic criteria for neuromyelitis optica. Neurology (2006) 17.57
A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet (2004) 13.18
IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med (2005) 10.39
The clinical course of neuromyelitis optica (Devic's syndrome). Neurology (1999) 8.03
A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain (2002) 6.85
Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol (2006) 2.80
A statistically defined endpoint titer determination method for immunoassays. J Immunol Methods (1998) 2.79
Neuromyelitis optica: clinical predictors of a relapsing course and survival. Neurology (2003) 2.28
Clinical, CSF, and MRI findings in Devic's neuromyelitis optica. J Neurol Neurosurg Psychiatry (1996) 2.02
Neuromyelitis optica. Semin Neurol (2002) 1.48
Devic's neuromyelitis optica: clinical, laboratory, MRI and outcome profile. J Neurol Sci (2002) 1.33
Neuromyelitis optica and anti-aquaporin-4 antibodies: widening the clinical phenotype. J Neurol Neurosurg Psychiatry (2006) 0.89
A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med (2010) 13.70
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature (2011) 13.23
Causes of encephalitis and differences in their clinical presentations in England: a multicentre, population-based prospective study. Lancet Infect Dis (2010) 7.60
Polymyositis and dermatomyositis. Lancet (2003) 7.24
Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Ann Neurol (2011) 6.77
Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet (2013) 4.62
Open letter to prime minister David Cameron and health secretary Andrew Lansley. BMJ (2010) 4.52
Immunoproteasomes preserve protein homeostasis upon interferon-induced oxidative stress. Cell (2010) 4.45
Comprehensive research synopsis and systematic meta-analyses in Parkinson's disease genetics: The PDGene database. PLoS Genet (2012) 4.27
Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain (2010) 3.95
Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology (2012) 3.67
Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci. Ann Neurol (2011) 3.52
Faciobrachial dystonic seizures: the influence of immunotherapy on seizure control and prevention of cognitive impairment in a broadening phenotype. Brain (2013) 3.22
In vivo imaging of partially reversible th17 cell-induced neuronal dysfunction in the course of encephalomyelitis. Immunity (2010) 3.18
Morvan syndrome: clinical and serological observations in 29 cases. Ann Neurol (2012) 3.12
Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. J Neuroinflammation (2012) 3.12
IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis. Brain (2008) 2.91
Laparoscopic sigmoid resection for diverticulitis decreases major morbidity rates: a randomized control trial: short-term results of the Sigma Trial. Ann Surg (2009) 2.89
Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J Exp Med (2007) 2.88
Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution. Neurology (2013) 2.77
Phenotypic variants of autoimmune peripheral nerve hyperexcitability. Brain (2002) 2.77
MicroRNA profiling of multiple sclerosis lesions identifies modulators of the regulatory protein CD47. Brain (2009) 2.74
Sirt1 contributes critically to the redox-dependent fate of neural progenitors. Nat Cell Biol (2008) 2.71
Antibodies to glutamic acid decarboxylase define a form of limbic encephalitis. Ann Neurol (2010) 2.54
B lineage cells in the inflammatory central nervous system environment: migration, maintenance, local antibody production, and therapeutic modulation. Ann Neurol (2006) 2.52
Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis. Arch Neurol (2008) 2.48
Autoantibodies in sporadic Creutzfeldt-Jakob disease. JAMA Neurol (2013) 2.42
Mechanisms of disease: aquaporin-4 antibodies in neuromyelitis optica. Nat Clin Pract Neurol (2008) 2.40
Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders. J Neuroinflammation (2011) 2.35
Clinical relevance of positive voltage-gated potassium channel (VGKC)-complex antibodies: experience from a tertiary referral centre. J Neurol Neurosurg Psychiatry (2013) 2.33
Disease-relevant autoantibodies in first episode schizophrenia. J Neurol (2010) 2.33
Acid-sensing ion channel-1 contributes to axonal degeneration in autoimmune inflammation of the central nervous system. Nat Med (2007) 2.28
Diagnostic value of N-methyl-D-aspartate receptor antibodies in women with new-onset epilepsy. Arch Neurol (2009) 2.25
Neuromyotonia and limbic encephalitis sera target mature Shaker-type K+ channels: subunit specificity correlates with clinical manifestations. Brain (2006) 2.25
Anti-N-methyl-D-aspartate receptor antibodies: a potentially treatable cause of encephalitis in the intensive care unit. Crit Care Med (2010) 2.24
Central nervous system neuronal surface antibody associated syndromes: review and guidelines for recognition. J Neurol Neurosurg Psychiatry (2012) 2.21
Thalamic neurodegeneration in multiple sclerosis. Ann Neurol (2002) 2.20
Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol (2011) 2.19
Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment. Brain (2005) 2.17
Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis. Brain (2012) 2.17
Paediatric autoimmune encephalopathies: clinical features, laboratory investigations and outcomes in patients with or without antibodies to known central nervous system autoantigens. J Neurol Neurosurg Psychiatry (2012) 2.15
Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol (2012) 2.12
Neurofascin as a target for autoantibodies in peripheral neuropathies. Neurology (2012) 2.09
Indolamine 2,3-dioxygenase is expressed in the CNS and down-regulates autoimmune inflammation. FASEB J (2005) 2.04
N-methyl-D-aspartate receptor antibodies in pediatric dyskinetic encephalitis lethargica. Ann Neurol (2009) 2.03
Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor. Brain (2002) 2.02
Voltage-gated potassium channel antibodies in limbic encephalitis. Ann Neurol (2003) 2.02
Neuronal damage in autoimmune neuroinflammation mediated by the death ligand TRAIL. Neuron (2005) 2.01
Interferon Beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers. Arch Neurol (2010) 1.99
The impact of sleep deprivation on product quality and procedure effectiveness in a laparoscopic physical simulator: a randomized controlled trial. Am J Surg (2005) 1.95
Multiple sclerosis: T-cell receptor expression in distinct brain regions. Brain (2007) 1.94
BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J Exp Med (2005) 1.92
GRIN2A mutations in acquired epileptic aphasia and related childhood focal epilepsies and encephalopathies with speech and language dysfunction. Nat Genet (2013) 1.91
Autoimmunity against the β2 adrenergic receptor and muscarinic-2 receptor in complex regional pain syndrome. Pain (2011) 1.89
Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann Neurol (2004) 1.89
Dok-7 mutations underlie a neuromuscular junction synaptopathy. Science (2006) 1.88
MR-elastography reveals degradation of tissue integrity in multiple sclerosis. Neuroimage (2009) 1.83
Myasthenia in pregnancy: best practice guidelines from a U.K. multispecialty working group. J Neurol Neurosurg Psychiatry (2013) 1.83
Multiple sclerosis: brain-infiltrating CD8+ T cells persist as clonal expansions in the cerebrospinal fluid and blood. Proc Natl Acad Sci U S A (2004) 1.80
B cells and antibodies in multiple sclerosis pathogenesis and therapy. Nat Rev Neurol (2012) 1.80
Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol (2013) 1.79
Neurofascin as a novel target for autoantibody-mediated axonal injury. J Exp Med (2007) 1.77
Changes in cerebral perfusion precede plaque formation in multiple sclerosis: a longitudinal perfusion MRI study. Brain (2003) 1.75
Postinfectious neurologic syndromes: a prospective cohort study. Neurology (2013) 1.73
Impairment of contrast visual acuity as a functional correlate of retinal nerve fibre layer thinning and total macular volume reduction in multiple sclerosis. Br J Ophthalmol (2011) 1.73
Matching of oligoclonal immunoglobulin transcriptomes and proteomes of cerebrospinal fluid in multiple sclerosis. Nat Med (2008) 1.72
Determinants of recurrence after sigmoid resection for uncomplicated diverticulitis. Dis Colon Rectum (2003) 1.70
Complication rates after Hartmann's reversal: open vs. laparoscopic approach. Dis Colon Rectum (2008) 1.69
Characteristics of Susac syndrome: a review of all reported cases. Nat Rev Neurol (2013) 1.69
Maternal neuronal antibodies associated with autism and a language disorder. Ann Neurol (2003) 1.69
Patterns of antibody binding to aquaporin-4 isoforms in neuromyelitis optica. PLoS One (2010) 1.68
The brain as a target of inflammation: common pathways link inflammatory and neurodegenerative diseases. Trends Neurosci (2006) 1.68
Presence and pathogenic relevance of antibodies to clustered acetylcholine receptor in ocular and generalized myasthenia gravis. Arch Neurol (2012) 1.67
Distinct lesion morphology at 7-T MRI differentiates neuromyelitis optica from multiple sclerosis. Neurology (2012) 1.67
Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain (2012) 1.65
Extracellular matrix in multiple sclerosis lesions: Fibrillar collagens, biglycan and decorin are upregulated and associated with infiltrating immune cells. Brain Pathol (2010) 1.61
Detection of anti-aquaporin-4 antibodies in neuromyelitis optica: current status of the assays. Int MS J (2008) 1.61
Cerebrospinal fluid antibodies to aquaporin-4 in neuromyelitis optica and related disorders: frequency, origin, and diagnostic relevance. J Neuroinflammation (2010) 1.60
How to treat tumefactive demyelinating disease? Mult Scler (2013) 1.59
Low frequency of MuSK antibody in generalized seronegative myasthenia gravis among Chinese. Neurology (2004) 1.56
Idiosyncratic adverse reactions to antiepileptic drugs. Epilepsia (2007) 1.56
N-methyl-D-aspartate receptor antibodies in post-herpes simplex virus encephalitis neurological relapse. Mov Disord (2013) 1.55